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Abstract 
Metals are accumulated mainly in the kidney during cancer therapy with metal complexes. Since liver 
is the most important organ for metabolism of the chemicals, the function of it can determine the 
effectiveness of therapy because of joint side effect of different chemicals in the liver. Therefore our 
aim was to study the concentration of essential elements Ca, Co, Cu, Fe, K, Mg, Mn, Mo, Na, P, S, Zn 
and antioxidant status in liver of rats after treatment with cisplatin and CV247 product which contains 
Cu and Mn gluconate, ascorbic acid and Na salicylate. Male Wistar rats (n=40, 175-190 g) were 
randomly divided into 4 groups (n=10/group). The control group received 1% (w/v) methyl cellulose at 
10 mL/kg body weight, p.o. by gastric gavage twice daily for 14 days, while cisplatin was injected i.p. 
in a single dose of 6.5 mg/kg body weight. The CV247 treated group received 3 mL CV247/kg body 
weight, p.o. twice daily for 14 days. The forth group of rats was treated with cisplatin and CV247 in 
the mentioned doses. Inductively coupled plasma optical emission spectrometry (ICP-OES) was used 
for measuring Ca, Co, Cu, Fe, K, Mg, Mn, Mo, P, S, Zn in the liver and total scavenger capacity and 
diene conjugate content were also determined. Element depletion was found in the liver of both rat 
groups treated with CV247, nevertheless the oxidative stress caused by cisplatin was diminished by 
CV247. But these results pay attention to the importance of essential element, such as Ca and Mg 
supply as well in cancer therapy. 
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Abbreviations: 
AP-1=transcription factor 1; CDDP=cisplatin,  cis-diamminedichloroplatinum II;  
COX=cyclooxigenase; CV247=copper-manganese gluconate with ascorbic acid and sodium salicylate; 
DL=detection limit; DV=declared value, FV=finale volume; GSHPx=gluthatione peroxidase; HHT=12-
hydroxy-5,8,10-heptadecatrienoic acid; ICP-OES= inductively coupled plasma optical emission 
spectrometry; IDL=instrumental detection limit; 6-keto-PGF1α=6-keto-prostaglandin F1alpha; 
LOO•=lipid-peroxid radical; MV=measured value, NF-κB=nuclear factor κB; 15-d-PGJ2=15-deoxy-
delta12,14- prostaglandin J2; 19-OH-PGA2=19(R)-hydroxyprostaglandin A2; 19-OH-PGE2=19(R)-
hydroxyprostaglandin E2; 19-OH-PGF2 α=19(R)-hydroxyprostaglandin F2alpha; PGA2=prostaglandin 
A2; PGD2=prostaglandin D2; PGE2=prostaglandin E2;  PGF2α=prostaglandin F2alpha; 
PGG2=prostaglandin G2; PGH2=prostaglandin H2 ; PGI2=prostacyclin; R=recovery; RLU=relative 
light unit; SOD=superoxide dismutase; TXA2=tromboxán A2; TXB2=tromboxán B2; W=weight of 
sample 
 
 
Introduction 
Platinum complexes such as cisplatin, oxaliplatin and carboplatin are widely used in cancer therapy 
against several tumors. The most frequently used platinum derivative in head and neck squamous cell 
carcinoma, testicular, ovarian and bladder carcinomas, and non–small cell lung cancers is cisplatin (cis-
diamminedichloroplatinum II, CDDP) [Bose 2002]. Its serious side effect on kidney is well known but 
it has effect on liver as well, since cisplatin is significantly metabolized by the liver [Liao et al. 2008, 
Máthé et al. 2014, Naziroglu et al. 2004]. Histopathological investigations justified that cisplatin 
induces severe liver damage such as degenerative hepatocytes and moderate enlargement of sinusoids 
[Miyamoto et al. 2007, Lynch et al. 2005]. The prevention of cisplatin side effects was solved with 
antioxidant treatment with e.g. selenium, vitamin C, ellagic acid, lycopene, resveratrol and  macelignan 
[Bompart 1989, Amaral et al. 2008, Miyamoto et al. 2007, Yüce et al. 2007, Sohn et al. 2008, Sezen et 
al. 2008]. Vitamin E and L-carnitine separately or in combination could be effective in the prevention 
of radiation-induced brain and retinal damages [Al-Majed 2007].  
The endogenously synthesized L-carnitine effectively inhibits the mitochondrial damage induced by 
oxidative stress and mitochondria-dependent apoptosis of various types of cells. Carnitine deficiency 
provokes cisplatin-induced hepatotoxicity in rats [Aleisa et al. 2007]. L-carnitine has also a significant 
protective effect on the liver and kidney in cisplatin induced oxidative damage by decreasing the lipid 
peroxidation and elevating the level of glutathione and the activation of glutathione peroxidase, 
glutathione-S-transferases, and SOD. L-carnitine treatment reduces the sinusoidal dilatation, 
congestion, and mononuclear cell infiltration of portal area in liver as well as tubular desquamation and 
dilatation of collective tubules in kidney [Sener et al. 2004]. 
Toxic effects of metals are displayed via oxidative mechanisms [Stohs and Bagchi 1995], therefore the 
joint examination of redox and metal homeostasis in the body is necessary. Cisplatin also affects by 
this mechanism and damages organs, tissues, cells. The most toxic effect appears in the kidney, where 
Pt is accumulated [Sabolic 2003, Kim et al. 2004] nevertheless in cancer therapy the liver could be 
damaged seriously because of the side effects and by the several medicines consumed. Therefore 
investigation of the liver has a great significance in our days because many thousands of medicine can 
cause liver damage and the joint application of these drugs can cause more serious problems [Meier et 
al. 2005]. 
Since several elements (Cu, Zn, Mn, Fe, Se) and metal enzymes (e.g. SOD, catalase, GSHPx) as well 
as ascorbic acid have a role in the antioxidant system [Zablocka and Janus 2008], we were interested in 
whether supplementation of Cu and Mn from these metals in organic complex form and ascorbic acid 
component of the well documented CV247 product can protect the oxidative stress in the liver caused 
by Pt containing cisplatin and how it is able to modify the metal element content in the liver.  
 
Materials and methods 
Test material 
Cisplatin (10 mg in 20 mL) was originated from TEVA Pharmaceutical Industries, Petach Tikva, Israel. 
The CV247 solution (40 mg ascorbic acid, 2 mg manganese gluconate, 2 mg copper gluconate, 35 mg 
sodium salicylate per millilitre solution) was obtained from Pharmaserve Ltd, Manchester UK 
(www.ivymedical.com). Methyl cellulose mucilage (Dow Chemicals) was prepared in distilled water 
(1%).  
Luminol, hydrogen peroxide  and microperoxidase were obtained from SIGMA (St.Luis), serum 
bovine albumin from CALBIOCHEM AG (Lucerne). All other reagents were purchased from Reanal 
Chemical Company (Budapest). 
 
Animal experiment 
Forty 8-week-old Wistar HsdCpb young male rats weighting 175-190 g were randomly divided into 4 
groups (n=10/group). The control group received 1% (w/v) methyl cellulose at 10 mL/kg body weight 
p.o. by gastric gavage twice daily for 14 days. The cisplatin treated group received cisplatin in 
intraperitoneal injection with a single dose of 6.5 mg/kg body weight in 10 mL/kg 1% methyl cellulose 
mucin vehicle [Ognjanovic et al. 2012]. The CV247 treated group got CV247 at 3 mL/kg body weight, 
p.o. twice daily for 14 days. The forth group of rats was treated with cisplatin and CV247 in the above 
mentioned doses. On the 14th day the rats were weighted then terminally anaesthetised with 
pentobarbitone.  
The animals were kept individually under standard conventional conditions according to European 
Council Directive 123. The study conformed to the Declaration of Helsinki guidelines and was 
approved by the local animal ethical committee. 
Citrated blood samples were taken from the jugular vein 48 hours before the planned terminal 
euthanasia after 20 hours starvation. For proving the effect of cisplatin to renal dysfunction, blood urea 
nitrogen (BUN) and creatinin levels were measured on day 12 besides general routine parameters and 
essential element concentration in plasma, histological investigation and element content changes in 
kidney as it was published earlier [Máthé et al. 2013].  
 
 
Rat samples 
The liver was removed, weighed, washed and then homogenized in ice-cold isotonic KCl solution and 
the protein concentration was set at 10 g/L.  
 
Measurement of protein content of liver homogenates 
The protein content of liver homogenates was measured by Lowry et al. The protein concentration of 
all homogenates was adjusted to 10 mg/ml using bovine albumin as standard for the measurements 
[Lowry et al. 1951].  
 
Measurement of metal content 
Homogenized liver samples were weighed (3.0-3.5 g liver homogenate) into the digestion vessels and 
digested with 5 mL 65% nitric acid and 2 mL hydrogen peroxide. The digestion was performed in a 
block digestion system because of the large amount of samples. After digestion and evaporation to 
small volume, the samples were poured into 10 mL volumetric flasks and were filled up to the mark 
with bidistilled water. Three liver samples were prepared from each animal. 
Inductively coupled plasma optical emission spectrometric (ICP-OES) method was applied for 
measuring Ca, Co, Cu, Fe, K, Mg, Mn, Mo, Na, P, S, Zn and Pt content using a Spectro  Genesis ICP-
OES (Kleve, Germany) equipment by the method applied earlier [Szentmihályi et al. 2004]. For the 
standardization of equipment and measurements, Spectro multi-element and Spectrum 3D standards 
were used. Standards were prepared in the same matrix as the samples. The samples were measured 3 
times and blank subtraction was applied.  
Metal element concentrations in bovine liver solution (High Purity Standards, CRM BL 411213) were 
measured for the demonstration of reliability and precision of the measurement (Table 1). The recovery 
(R) was calculated from the declared (DV) and measured values (MV) as follows: R=MV/DV*100. In 
the case of Mo and Pt, which had no certified values, the repeatability measurements were performed 
(five times) with standard solutions of 0.2 μg/mL and 0.5 μg/mL concentrations, and the recovery was 
calculated from these results (Table 1). 
The detection limit (DL) for Pt in the samples was calculated from the instrumental detection limit 
(IDL) of it, the weights of sample (W) and the final volume (FV) as follows: DL=IDL*FV/W. The 
below detection limit concentration for Pt was marked by the less-than sign (<). 
 
 
Table 1. Results of element concentration (mean±SD, μg/mL) in reference solution (Bovin liver 
solution, High Purity Standards, CRM BL 411213) standards and they recovery data 
 Declared 
concentration in 
reference solution 
Standard 
concentration 
Measured 
(n=5) 
Recovery 
(%) 
Ca 1.2  1.161±0.119 96.8 
Co 0.002  0.002±0.0001 100.0 
Cu 2.00  1.990±0.024 99.5 
Fe 3.00  2.893±0.018 96.4 
K 100.0  92.28±0.21 92.3 
Mg 6.00  5.837±0.123 97.3 
Mn 0.01  0.0948±0.0004 94.8 
Mo  0.2 0.206±0.008 103.1 
Na 25  25.09±0.02 100.4 
P 110  113.5±1.8 103.2 
Pt  0.5 0.493±0.018 98.7 
S 80.0  75.50±0.38 94.4 
Zn 1.5  1.477±0.028 98.5 
     
 
 
Measurement of redox parameters of the liver 
Total scavenger capacity (induced chemiluminescence assay) was determined with Berthold’s Lumat 
9501 luminometer on the basis of a method developed by Blázovics and coworkers [Blázovics et al.  
1999]. Chemiluminescent intensity of the liver homogenate was measured and expressed in relative 
light unit (RLU%) of the standard light (basic chemical reaction in H2O2/•OH–microperoxidase-
luminol system).  
Diene-conjugate content of the liver was determined at 233 nm by spectrophotometry by the AOAC 
method [1994]. 
In the liver homogenate malondialdehyde (MDA) levels were also measured spectrophotometrically by 
the method of Mansour and coworkers [mansour et al. 2006].  
 
 
Statistical calculations 
Means and standard deviations were calculated with MS-Excel, ANOVA and Kruskal-Wallis ANOVA 
were applied for the determination of significant differences between groups by using STATISTICA 11 
software. The level of significance was set at P<0.05. 
 
Results 
According to the literature cisplatin can generate reactive oxygen and nitrogen species by increasing 
the activity of the cytochrome P450 system, NADPH oxidases, xanthine oxidase and adenosine 
deaminase and cisplatin depletes the glutathione and inhibits the activity of antioxidant enzymes 
[Somani et al. 2000, Jiang and Dang 2008, Sung et al. 2008, Yilmaz et al. 2005, Koc et al. 2005, Ajih et 
al. 2007]. Nevertheless in our “short term” experiment cisplatin and CV247 alone didn’t induce the 
P450 system in the liver since the ratio of liver weight to body weight didn’t change at all or 
significantly, while the double treatment with cisplatin + CV247 induced it significantly (Table 2).   
 
Table 2. Changes of liver weight/body weight ratio by the administration of cisplatin and CV247 
 Control Cisplatin CV247 Cisplatin + 
CV247 
ANOVA 
sign. at 
P<0.05 
Liver 
weight
/body 
weight 
0.04214±0.00160 0.04215±0.00281 0.04542±0.02203 0.04775±0.00223 Sign. 
 
Redox parameters in the liver 
The total scavenger capacity in the liver of cisplatin-treated rats decreased as the amount of •OH/H2O2 
radicals in the H2O2/•OH-microperoxidase-luminol-system was considerably higher in the liver of rats 
treated with cisplatin than in the liver of rats in control group (Table 3). The treatment with CV247 did 
not change notably the total scavenger capacity while the CV247 treatment was able to decrease the 
formation of free radicals by the effect of cisplatin as the total scavenger capacity was decreased 
significantly. 
The diene conjugate level in the liver doesn’t show any significant change while malondialdehyde 
content in liver increased non-significantly by the effect of cisplatin treatment (Table 3).  
 
 
Table 3. Redox parameters in the liver  
 Control Cisplatin CV247 Cisplatin + 
CV247 
Kruskal-Wallis 
ANOVA sign. at 
P<0.05 
Induced 
chemiluminescence 
(RLU%) 
4.24±2.78 38.22±26.34 
 
3.98±5.13 5.50±10.37 Sign. 
Dién conjugate 
content 
0.207±0.036 0.175±0.035 0.203±0.032 0.226±0.036 Not sign. 
MDA content 
(nmol/l) 
20.3±5.4 32.9±7.5 25.2±5.6 33.2±8.7 Not sign. 
 
 
Element changes in the liver 
The element content and the significant changes in the liver by the effect of treatments can be seen in 
Table 4.  Significant concentration changes could be seen for the four groups in the case of Ca, Mg, 
Mn, Mo and Na using ANOVA test  at P<0.05. The cisplatin treatment increased the Fe concentration 
in liver, which may cause the increase of free radical reactions as it was shown in Table 3, while 
CV247 treatment decreased the Fe concentration. By the treatment with CV247 the Ca, Cu, Mg, Mn, 
Mo and Sr concentrations in the liver decreased. The joint treatment with cisplatin and CV247 caused 
significant decreasing in Ca, Cu, Fe, Mg, Mn, Mo, Na concentrations compared to cisplatin group 
which was worse than in case of the group treated with CV247 alone.  This means that the post-
treatment with CV247 was not able to protect the liver from the toxic effect of Pt and the combined 
treatment damaged the liver more seriously. The cisplatin treatment changes several metabolit 
concentrations, energy homeostases, and therefore ATP concentration also varies (Rodriguez-Enriquez 
et al. 2009), nevertheless in our experiment only a non-significant decreasing could be seen for P 
concentration in the liver of group treated with cisplatin+CV247. 
 
 
Table 4.  Element concentration (μg/g)  in rat liver  measured by ICP-OES 
 Control Cisplatin CV247 Cisplatin + 
CV247 
ANOVA sign. at 
P<0.05 
Ca 6.31±2.36 6.72±1.34 2.36±0.89 1.74±0.53 Sign. 
Co 0.005±0.002 0.006±0.003 0.005±0.002 0.004±0.001 Not sign 
Cu 0.189±0.047 0.188±0.024 0.168±0.023 0.153±0.029 Not sign 
Fe 4.01±1.20 6.55±2.04 3.63±0.34 3.42±0.92 Not sign 
K 1275±462 1377±139 1312±336 1261±229 Not sign 
Mg 11.23±3.63 11.56±1.46 6.96±0.70 6.19±0.89 Sign. 
Mn 0.098±0.028 0.098±0.008 0.080±0.008 0.071±0.012 Sign. 
Mo 0.030±0.005 0.028±0.008 0.026±0.003 0.023±0.004 Sign. 
Na 20.59±6.24 21.07±3.82 16.39±4.71 15.28±2.89 Sign. 
P 129.7±44.7 135.4±19.6 116.4±15.7 109.6±18.8 Not sign 
S 71.60±25.21 72.51±12.56 65.43±9.99 62.02±11.91 Not sign 
Zn 1.10±0.34 1.09±0.20 1.03±0.18 0.940±0.250 Not sign 
Pt <0.010 0.021±0.001 <0.010 <0.010  
 
 
Discussion 
The cisplatin treatment elevated the Fe and Pt concentrations in the liver which are unfavorable, since 
they may induce free radical reactions and elevate the free radical level. The mean part of the increased 
free radical level may be connected to radicals formed by Fe(II) induced Fenton reaction while smaller 
part of free radicals comes from the platinum radicals formed by metabolism of cisplatin [Naziroglu et 
al. 2004, Stohs and Bagchi 1995].  The CV247 product was able to diminish the oxidative stress in the 
liver which may due to ascorbic acid, salicylic acid, Cu and Mn as well. These metals have significant 
role in the antioxidant system as a central part of SOD enzymes [Zablocka and Janus 2008] 
nevertheless a decreasing concentration of Cu and Mn was observed in the liver despite of the 
supplementation. 
Salicylic acid is a good antiinflammatory agent and has direct and indirect antioxidant properties via 
several mechanisms, e.g. inhibits the prostaglandin (PG) biosynthesis routes [Baltazar et al. 2011, 
Borges et al. 2013].  Therefore free radicals are formed at the PGG2 and PGH2 synthesis steps and 
inhibits the expression of cyclooxygenases (Figure 1).  COX2 inhibition is favorable in the process but 
the inhibition of COX1 causes unwanted and harmful side effects in the gastrointestinal tract [Agundez 
et al. 2009, Kneitz et al. 2006, Szentmihályi et al. 2013]. 
Ascorbic acid content of CV247 also diminishes the free radical formations in different ways. Direct 
antioxidant activity was proven in several in vitro and in vivo studies, it is able to transform α-
tocopheroxyl radical to vitamin E [Packer 1979].   Nowadays its prooxidant activity was also proven 
via the transcription factors NF kappaB and AP1 activities, which induce gene expression of 
antioxidant enzymes and repair mechanisms as it could be seen in Fig.1 [Cooke 2000, 2002, Lunec et 
al. 2001, Puskás 2000, Blázovics 2007]. The AP1 activation increases the oxidative damage of DNA by 
oxidation or reduction of thiol group. In this process AP1 binds to DNA which induces the 
transactivation of DNA repair genes [Kaina 1998]. According to the molecular biological researches in 
the last years the possible repearing and impering effect of DNA has been known [Cooke 2000, 2002, 
Lunec 2002].  Ascorbic acid regulates the repair of 8-oxoG by redox way [Kaina 1998, Lunec et al. 
2002]. The dose dependent antioxidant and prooxidant properties of ascorbic acid is in connection to 
the attendant metal ions as well. Ascorbic acid in small concentration has prooxidant activity which is 
enhanced by the presence of Fe as well [Tsuchiya 1998].  
The examination of liver calls attention to that double treatment with cisplatin and CV247 product 
changes the whole metal homeostasis and the depletion of elements in the liver could be observed. The 
decreasing concentration of Ca and Mg in both CV247 treated groups and the decreasing concentration 
of Cu and Mn in cisplatin+CV247 treated group are particularly unfavorable. Furthermore the Ca to 
Mg concentration ratio in both CV247 treated groups reduced notably from 0.562 (control group) to 
0.339 at CV247 treated group and to 0.280 at double treated group. Although this ratio affects against 
the oxidative stress [Szentmihályi et al. 2013], the decrease of absolute concentration of Ca and Mg is 
unfavorable in the function of the liver. According to the results it is worthy to think about the 
supplementation of some essential elements in cancer therapy. 
Conclusion: Cisplatin treatment influences the metal element homeostasis and the redox homeostasis as 
well. The CV247 product acts different modes in different organs. Favorable effects on element and 
redox homeostasis were observed in plasma and kidney [Máthé et al. 2013].   In the liver it can also 
diminish the oxidative stress significantly after cisplatin therapy nevertheless the results show 
unwanted changes of metal element concentration during double treatment as well which can be 
possible prevented by additional supplementation of metals as Ca, Mg during the treatment. 
In this animal experiment salicylic acid was used as an antioxidant component of the agent and it its 
effectiveness was proved. In human study flavonoids can be applied for avoiding the harmful oxidative 
effect of cisplatin instead of salicylic acid which supposed to be as good as salicylic acid or better than 
that of [Blázovics et al. 1992, 2002, 2007] 
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Figure 1. Molecular biological effects of salicylic acid, ascorbic acid and metals of CV247. The figure 
was designed by the works of Lunec et al. 2002, Blázovics 2007 and Szentmihályi et al. 2013. 
(AP-1 = transcription factor 1; HHT=12-hydroxy-5,8,10-heptadecatrienoic acid; 6-keto-PGF1α= 6-
keto-prostaglandin F1alpha; LOO• = lipid-peroxid radical; NF-κB = nuclear factor κB; 15-d-PGJ2= 15-
deoxy-delta12,14- prostaglandin J2; 19-OH-PGA2= 19(R)-hydroxyprostaglandin A2; 19-OH-PGE2= 
19(R)-hydroxyprostaglandin E2; 19-OH-PGF2 α = 19(R)-hydroxyprostaglandin F2alpha; PGA2= 
prostaglandin A2; PGD2= prostaglandin D2; PGE2= prostaglandin E2;  PGF2α = prostaglandin F2alpha; 
PGG2= prostaglandin G2; PGH2=prostaglandin H2 ; PGI2 = prostacyclin; SOD = superoxide dismutase; 
TXA2 =tromboxán A2; TXB2 =tromboxán B2) 
 
 
 
 
